Generate Biomedicines, Inc. Common Stock (GENB)
PHARMACEUTICAL PREPARATIONS
Generate Biomedicines, Inc. Common Stock (GENB) is listed on Nasdaq, where it has traded since February 27, 2026.
- Listed On
- Nasdaq
- Listed Since
- February 27, 2026
- Market Cap
- $1.8B
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 83 institutions reported holding GENB, with 100.0 million shares worth $1.7 billion in aggregate. The largest reported holder was Flagship Pioneering, with 62.7 million shares worth $1.1 billion. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Flagship Pioneering | 62,673,117 | $1.1B | Unchanged |
| FMR | 5,221,599 | $88M | Added 23.81% |
| Capital Group | 4,215,632 | $71M | Added 5.28% |
| Braidwell | 3,283,844 | $55M | Reduced 8.6% |
| T. Rowe Price | 2,156,627 | $36M | Added 2.23% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is GENB?
Generate Biomedicines, Inc. Common Stock (GENB) is listed on Nasdaq, where it has traded since February 27, 2026.
Who are the largest institutional holders of GENB?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of GENB were Flagship Pioneering, FMR and Capital Group.
How many institutions own GENB?
83 institutions reported a position in GENB for the quarter ended June 30, 2026, worth $1.7 billion in total.
Did institutions buy or sell GENB last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for GENB.
Every reported institutional holder, plus insider and congressional trades in GENB, on SentiSense.